Literature DB >> 10655565

Flow cytometric visualisation of cytokine production by CD3-CD56+ NK cells and CD3+CD56+ NK-T cells in whole blood.

R Mendes1, K V Bromelow, M Westby, J Galea-Lauri, I E Smith, M E O'Brien, B E Souberbielle.   

Abstract

BACKGROUND: Natural killer (NK) cells produce multiple cytokines with potential immune regulatory roles. We standardised a whole-blood flow cytometry method to visualise intracellular cytokine production by NK cells for the study of NK cell biology and for clinical monitoring.
METHODS: With a three-colour fluorescent labelling technique, specific cytokine production by NK or T cells was visualised directly in whole blood in the same sample after stimulation by phorbol 12-myristate 13-acetate (PMA) and ionomycin and by electronically gating on the CD3-ve/CD56+ve NK population or on the CD3+/CD56+ NK-T-cell population.
RESULTS: Detectable levels of tumour necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) but not of interleukin-2 (IL-2) or IL-4 were easily observed in NK cells. The visualisation of the cytokine production by NK cells was dependent on the addition of a Golgi transport inhibitor, Brefeldin A. Other known stimuli for NK cells (IL-2 and CD16 monoclonal antibody and incubation with K562, the NK-sensitive cell line) promoted IFN-gamma and TNF-alpha production in NK cells to a lesser extent than did PMA and ionomycin stimulation.
CONCLUSIONS: This whole-blood flow cytometric assay appears to be an useful and easy method to examine cytokine production by NK cells and/or by CD3+CD56+ NK-T lymphocytes in patients with relevant diseases. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10655565     DOI: 10.1002/(sici)1097-0320(20000101)39:1<72::aid-cyto10>3.0.co;2-r

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  9 in total

1.  Evaluation of natural killer cell activity.

Authors:  J H Cox; M deSouza
Journal:  Mol Biotechnol       Date:  2000-06       Impact factor: 2.695

2.  CD3+CD56+ NK T cells are significantly decreased in the peripheral blood of patients with psoriasis.

Authors:  A Koreck; A Surányi; B J Szöny; A Farkas; Z Bata-Csörgö; L Kemény; A Dobozy
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

3.  Effects of ovarian steroids on immunoglobulin-secreting cell function in healthy women.

Authors:  Fabien X Lü; Zhongmin Ma; Susie Moser; Thomas G Evans; Christopher J Miller
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

4.  3D porous chitosan-alginate scaffolds: a new matrix for studying prostate cancer cell-lymphocyte interactions in vitro.

Authors:  Stephen J Florczyk; Gang Liu; Forrest M Kievit; Allison M Lewis; Jennifer D Wu; Miqin Zhang
Journal:  Adv Healthc Mater       Date:  2012-07-06       Impact factor: 9.933

5.  NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab.

Authors:  Alfredomaria Lurati; Luca Bertani; Mariagrazia Marrazza; Katia Angela Re; Daniela Bompane; Magda Scarpellini
Journal:  Biologics       Date:  2012-04-11

6.  Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma.

Authors:  R Mendes; M E R O'Brien; A Mitra; A Norton; R K Gregory; A R Padhani; K V Bromelow; A R Winkley; S Ashley; I E Smith; B E Souberbielle
Journal:  Br J Cancer       Date:  2002-02-01       Impact factor: 7.640

7.  A change of PD-1/PD-L1 expression on peripheral T cell subsets correlates with the different stages of Alzheimer's Disease.

Authors:  Ching-Tse Wu; Cheng-I Chu; Feng-Yu Wang; Hui-Yu Yang; Wei-Sung Tseng; Chuang-Rung Chang; Chien-Chung Chang
Journal:  Cell Biosci       Date:  2022-09-30       Impact factor: 9.584

8.  Relationship between NK Cell Activation and Clinical Response in Rheumatoid Arthritis Treated with Rituximab.

Authors:  A Lurati; M G Marrazza; K A Re; M Scarpellini
Journal:  Int J Biomed Sci       Date:  2009-06

9.  Expression of NK (CD16+56+) and B cells (CD19) Receptor Molecules as a Reliable Clinical Response Biomarkers of SLE and RA Patients Under the Rituximab Treatment.

Authors:  Lamija Zecevic; Mevludin Mekic; Djemo Subasic; Majda Hadziabulic; Edmira Isak; Emina Subasic; Kenan Selmanovic
Journal:  Med Arch       Date:  2019-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.